During the last session, Biohaven Ltd (NYSE:BHVN)’s traded shares were 1.43 million, with the beta value of the company hitting 4.24. At the end of the trading day, the stock’s price was $18.68, reflecting an intraday gain of 0.65% or $0.12. The 52-week high for the BHVN share is $55.70, that puts it down -198.18 from that peak though still a striking 15.47% gain since the share price plummeted to a 52-week low of $15.79. The company’s market capitalization is $1.91B, and the average intraday trading volume over the past 10 days was 1.93 million shares, and the average trade volume was 1.16 million shares over the past three months.
Biohaven Ltd (BHVN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. BHVN has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.49.
Biohaven Ltd (NYSE:BHVN) trade information
Biohaven Ltd (BHVN) registered a 0.65% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.65% in intraday trading to $18.68, hitting a weekly high. The stock’s 5-day price performance is 0.05%, and it has moved by -35.25% in 30 days. Based on these gigs, the overall price performance for the year is -58.28%. The short interest in Biohaven Ltd (NYSE:BHVN) is 7.49 million shares and it means that shorts have 5.94 day(s) to cover.
The consensus price target of analysts on Wall Street is $60, which implies an increase of 68.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $57 and $61 respectively. As a result, BHVN is trading at a discount of -226.55% off the target high and -205.14% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.25M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 1.25M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -49.78%. While earnings are projected to return 26.30% in 2025, the next five years will return 22.09% per annum.
BHVN Dividends
Biohaven Ltd is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biohaven Ltd (NYSE:BHVN)’s Major holders
Biohaven Ltd insiders own 11.97% of total outstanding shares while institutional holders control 91.85%, with the float percentage being 104.33%. VANGUARD GROUP INC is the largest shareholder of the company, while 346.0 institutions own stock in it. As of 2024-06-30, the company held over 7.27 million shares (or 8.9114% of all shares), a total value of $252.41 million in shares.
The next largest institutional holding, with 6.48 million shares, is of STIFEL FINANCIAL CORP’s that is approximately 7.3839% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $224.94 million.
Also, the Mutual Funds coming in first place with the largest holdings of Biohaven Ltd (BHVN) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.51 shares. This amounts to just over 2.46 percent of the company’s overall shares, with a $46.9 million market value. The same data shows that the other fund manager holds slightly less at 2.26, or about 2.22% of the stock, which is worth about $42.25 million.
